ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

2019-nCoV Vaccine mRNA-1273

Also written as “mRNA-1273”, “mRNA-1273.815” and “mRNA-1273.529”.

Its studies are mostly in COVID-19 · Coronavirus Infections · Papillomavirus Infections · Influenza, Human, led by 4 companies.

Drug page2019-nCoV Vaccine mRNA-1273: every studyAll 41 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 3, 202420 company-led studies, 3 open or runningNext primary completion: Dec 11, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Modernaits history only173 open or runningphase 4since Sep 3, 2024May 13, 2020Dec 11, 2026phase 4 · NCT07863635
Merck10 open or runningphase 3since Nov 10, 2021Nov 10, 2021none ahead
Regeneron Pharmaceuticalsits history only10 open or runningphase 2since Apr 19, 2021Apr 19, 2021none ahead
Takedaits history only10 open or runningphase 2since Dec 18, 2020Dec 18, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 10, 2021First study: phase 3 study in Papillomavirus InfectionsFirst studyNCT05119855 · 165 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A vaccine consisting of a lipid nanoparticle (LNP) encapsulating a messenger RNA (mRNA) encoding the full-length, prefusion stabilized spike (S) protein of SARS-CoV-2, ”NCIt, by rule
“Spike glycoprotein vaccine antigen”ChEMBL 37, by rule

Studies

The one study Merck leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05119855Papillomavirus Infections · United States3CompletedDec 12, 2023165

How it is read

Names in the registry

  • “mRNA-1273”, 10 entries
  • “mRNA-1273.815”, 3 entries
  • “mRNA-1273.529”, 2 entries
  • “mRNA-1273 Variant-containing Formulation”, 1 entry
  • “mRNA-1273 Vaccine”, 1 entry

Codes read as this program: MRNA1273.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.